June 16, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Burosumab improves physical function, reduces pain in X-linked hypophosphatemia
CHICAGO — Burosumab is tied to greater improvements in pain, stiffness and physical function than active vitamin D and phosphate salts among patients with X-linked hypophosphatemia, according to data presented at ENDO 2026. Burosumab-twza (Crysvita, Kyowa Kirin), a monoclonal anti-fibroblast growth factor 23 antibody, was approved by the FDA as the first therapy to treat X-linked
874 words~4 min read
